Net Profit Margin: 16.40%
Is the net profit margin high or low?
The net profit margin of 16.40% is in line with its 5-year average of 16.65%, around the middle of its 5-year range (-5.58%–33.21%).
As of Saturday, June 27, 2026. 85.74% above its 12-month average of 8.83%.
TECH Profit Margin
Reported quarterly profit margin; no daily interpolation.
TECH Average Net Profit Margin Chart
TECH Current vs Average Net Profit Margin Chart
TECH Net Profit Margin Metrics
NET PROFIT MARGIN
16.40%
NET PROFIT MARGIN AVG TTM
8.83%
NET PROFIT MARGIN AVG 3Y
13.10%
NET PROFIT MARGIN AVG 5Y
17.76%
NET PROFIT MARGIN AVG 10Y
17.33%
NET PROFIT MARGIN AVG 15Y
21.59%
NET PROFIT MARGIN AVG 20Y
26.51%
CURRENT VS TTM AVG
+85.74%
CURRENT VS 3Y AVG
+25.17%
CURRENT VS 5Y AVG
-7.67%
CURRENT VS 10Y AVG
-5.37%
CURRENT VS 15Y AVG
-24.06%
CURRENT VS 20Y AVG
-38.15%
TECH Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 16.40% | 8.83% | 13.10% | 17.76% |
| Insulet Corp. (PODD)vs › | $10.96B | 10.44% | 14.66% | 10.46% | 7.35% |
| Baxter International Inc. (BAX)vs › | $11.38B | -9.70% | -7.30% | -3.29% | 1.14% |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 0.42% | 1.97% | 2.41% | 2.58% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -4.07% | -4.03% | -0.72% | 0.14% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | -4.59% | -1.67% | 5.09% | 7.31% |
| Tempus AI, Inc. (TEM)vs › | $9.80B | -22.20% | -60.53% | -62.93% | -77.31% |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 2.95% | 3.05% | 3.43% | 3.79% |
| Revvity, Inc. (RVTY)vs › | $12.61B | 8.30% | 9.60% | 8.02% | 12.66% |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 10.50% | 10.36% | 10.48% | 22.21% |
Margin Comparison
Operating Margin
12.7%
Net Profit Margin
16.4%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for Bio-Techne Corporation (TECH)?
- The net profit margin for TECH stock is 16.40%.
- Is Bio-Techne Corporation's net profit margin high or low?
- The net profit margin of 16.40% is in line with its 5-year average of 16.65%, around the middle of its 5-year range (-5.58%–33.21%).
- What is the TTM average net profit margin for Bio-Techne Corporation (TECH)?
- The TTM average net profit margin for TECH stock is 8.83%.
- What is the 3Y average net profit margin for Bio-Techne Corporation (TECH)?
- The 3Y average net profit margin for TECH stock is 13.10%.
- What is the 5Y average net profit margin for Bio-Techne Corporation (TECH)?
- The 5Y average net profit margin for TECH stock is 17.76%.
- What is the 10Y average net profit margin for Bio-Techne Corporation (TECH)?
- The 10Y average net profit margin for TECH stock is 17.33%.
- What is the 15Y average net profit margin for Bio-Techne Corporation (TECH)?
- The 15Y average net profit margin for TECH stock is 21.59%.
- What is the 20Y average net profit margin for Bio-Techne Corporation (TECH)?
- The 20Y average net profit margin for TECH stock is 26.51%.
TECH Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 16.40% |
| 2025-12-31 | 12.85% |
| 2025-09-30 | 13.33% |
| 2025-06-30 | -5.58% |
| 2025-03-31 | 7.14% |
| 2024-12-31 | 11.75% |
| 2024-09-30 | 11.61% |
| 2024-06-30 | 13.26% |
| 2024-03-31 | 16.17% |
| 2023-12-31 | 10.08% |
| 2023-09-30 | 18.41% |
| 2023-06-30 | 25.05% |
| 2023-03-31 | 23.87% |
| 2022-12-31 | 18.41% |
| 2022-09-30 | 33.21% |
| 2022-06-30 | 21.35% |
| 2022-03-31 | 20.92% |
| 2021-12-31 | 29.77% |
| 2021-09-30 | 27.01% |
| 2021-06-30 | 5.78% |
| 2021-03-31 | 18.80% |
| 2020-12-31 | 20.63% |
| 2020-09-30 | 16.35% |
| 2020-06-30 | 33.47% |
| 2020-03-31 | 18.71% |
| 2019-12-31 | 64.68% |
| 2019-09-30 | 7.86% |
| 2019-06-30 | 8.59% |
| 2019-03-31 | 24.16% |
| 2018-12-31 | 10.06% |
| 2018-09-30 | 10.68% |
| 2018-06-30 | 22.69% |
| 2018-03-31 | 12.04% |
| 2017-12-31 | 31.69% |
| 2017-09-30 | 10.97% |
| 2017-06-30 | 18.40% |
| 2017-03-31 | 14.85% |
| 2016-12-31 | 4.79% |
| 2016-09-30 | 12.47% |
| 2016-06-30 | 19.02% |
| 2016-03-31 | 23.13% |
| 2015-12-31 | 21.38% |
| 2015-09-30 | 20.21% |
| 2015-06-30 | 22.38% |
| 2015-03-31 | 21.28% |
| 2014-12-31 | 29.66% |
| 2014-09-30 | 22.04% |
| 2014-06-30 | 28.99% |
| 2014-03-31 | 33.11% |
| 2013-12-31 | 29.82% |
| 2013-09-30 | 32.02% |
| 2013-06-30 | 35.75% |
| 2013-03-31 | 40.89% |
| 2012-12-31 | 33.78% |
| 2012-09-30 | 34.21% |
| 2012-06-30 | 34.62% |
| 2012-03-31 | 37.98% |
| 2011-12-31 | 34.57% |
| 2011-09-30 | 35.47% |
| 2011-06-30 | 36.30% |
| 2011-03-31 | 40.73% |
| 2010-12-31 | 39.19% |
| 2010-09-30 | 38.82% |
| 2010-06-30 | 38.81% |
| 2010-03-31 | 46.09% |
| 2009-12-31 | 37.73% |
| 2009-09-30 | 40.24% |
| 2009-06-30 | 39.12% |
| 2009-03-31 | 40.73% |
| 2008-12-31 | 38.18% |
| 2008-09-30 | 41.25% |
| 2008-06-30 | 40.22% |
| 2008-03-31 | 42.56% |
| 2007-12-31 | 38.04% |
| 2007-09-30 | 39.79% |
| 2007-06-30 | 39.24% |
| 2007-03-31 | 39.69% |
| 2006-12-31 | 35.54% |
| 2006-09-30 | 37.50% |
| 2006-06-30 | 37.43% |
| 2006-03-31 | 37.12% |
| 2005-12-31 | 34.38% |
| 2005-09-30 | 35.63% |
| 2005-06-30 | 39.05% |
| 2005-03-31 | 38.47% |
| 2004-12-31 | 35.35% |
| 2004-09-30 | 34.68% |
| 2004-06-30 | 31.48% |
| 2004-03-31 | 34.36% |
| 2003-12-31 | 32.33% |
| 2003-09-30 | 33.09% |
| 2003-06-30 | 32.15% |
| 2003-03-31 | 32.84% |
| 2002-12-31 | 29.67% |
| 2002-09-30 | 30.23% |
| 2002-06-30 | -0.85% |
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman